Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195869 · ClinicalTrials.gov registry record · Phase 1
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT02195869 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 45 participants.
The verdict
NCT02195869, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
Interventions
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-07-14 |
| Est. Completion | 2017-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195869
The ClinicalTrials.gov registry entry for NCT02195869 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibrutinib is the first listed.
NCT02195869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195869 about?
NCT02195869 is a clinical study titled "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease". The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
What is the current status of trial NCT02195869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2014-07-14. Estimated completion is 2017-09-15.
What interventions are being tested in trial NCT02195869?
The interventions under investigation include: Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02195869?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.